{"source_content":"1Table_FirstTable_First|Table_ReportType证券研究报告行业点评Table_First|Table_Summary整体受益疫情，建议关注高成长可持续板块医药生物行业投资要点：医药工业受疫情影响收入增速有所下滑，整体仍呈现正增长。2020年规模以上医药制造业实现主营业务收入24857.3亿元，同比增长4.5%，增速较上年同期下降2.9个百分点；实现利润总额3506.7亿元，同比增长12.80%，增速较上年提升6.9个百分点。由于疫情原因，国内抗疫相关产业快速增长，叠加原料药涨价、部分海外业务转入国内等因素，2021年一季度医药制造业收入为6555.1亿，同比增长30.6%，行业利润为1147.6亿元，增速为86.88%，利润增速显著加快。上市公司整体受益疫情。2020年医药上市公司实现营收18928亿，增长7.18%，实现归母净利1586亿元，同比提升44.61%。2021年1季度实现营收5196亿，同比增长31.76%，实现归母净利润554亿，同比增加84.76%。各板块中，医疗器械中的检测试剂、第三方检测服务以及呼吸机、额温枪等产品直接受益疫情；生物制品领域，HPV疫苗、13价肺炎结合疫苗、流感疫苗放量，生长激素高增长。医疗服务中的CRO/CMO高增长。化学制剂板块受门诊量下降拖累，2020年整体下滑，但细分领域龙头（如人福）表现亮眼，创新药如大分子的PD-1单抗、小分子的安罗替尼等销售额增长迅速，在2020年二季度后销售逐步恢复；中药板块和化学制剂板块表现类似，门诊量下滑的影响消退。建议关注细分行业增长逻辑可持续的公司和创新药企。生物制品领域，疫苗、生长激素需求旺盛，新品上市、消费升级带动业绩；医药商业和医疗服务领域，连锁零售药店以及连锁医疗服务中的眼科、牙科业务依靠内生+外延扩张的模式持续，CRO/CMO类的公司受益研发项目数量增加、国内工程师红利以及海外订单转移，继续高增长；制药领域的细分龙头（麻醉、呼吸）格局好，创新药的多个企业（大分子、小分子）目前已进入收获期，建议关注以上细分板块和公司。风险提示政策性风险Table_First|Table_ReportDate2021年05月05日Table_First|Table_Rating投资建议：强于大市上次建议：强于大市Table_First|Table_Author夏禹分析师执业证书编号：S0590518070004电话：0510-82832787邮箱：yuxia@glsc.com.cnTable_First|Table_Chart一年内行业相对大盘走势Table_First|Table_ContacterTable_First|Table_RelateReport相关报告1、《坚守“创新”核心，拥抱“消费”景气》《医药生物》2021.01.11、《冠脉支架集采落地，器械耗材进入创新时代》《医药生物》2020.11.093、《拥抱NAFLD影像检测巨大蓝海市场》《医药生物》2020.07.08请务必阅读报告末页的重要声明-10%0%10%20%30%40%50%60%医药生物(申万)沪深3002请务必阅读报告末页的重要声明行业点评正文目录12020年医药工业整体情况........................................................................................32医药上市公司盈利能力分析......................................................................................32.1原料药.........................................................................................................42.2化学制剂.....................................................................................................52.3中药............................................................................................................62.4医疗器械.....................................................................................................72.5医疗服务.....................................................................................................82.6医药商业.....................................................................................................92.7生物制品...................................................................................................103风险提示.................................................................................................................113请务必阅读报告末页的重要声明行业点评12020年医药工业整体情况2020年医药制造业实现主营业务收入24857.3亿元，同比增长4.5%（统计局数据），增速较上年同期下降2.9个百分点；实现利润总额3506.7亿元，同比增长12.80%，增速较上年提升6.9个百分点。由于疫情原因，国内抗疫相关产业快速增长，叠加原料药涨价、部分海外业务转入国内等因素，2021年一季度医药制造业收入为6555.1亿，同比增长30.6%，一季度行业总利润为1147.6亿元，增速为86.88%（Wind行业数据）。2医药上市公司盈利能力分析上市公司方面，剔除部分不可比公司，医药行业整体保持了较高的增长态势，2020年医药上市公司实现营收18928亿，增长7.18%，增速同比下降6.42个百分点，实现归母净利1586亿元，同比提升44.61%。2021年1季度实现营收5196亿，同比增长31.76%，实现归母净利润554亿，同比增加84.76%。图表1：医药制造业2015年以来收入变化图表2：医药制造业2015年以来总利润变化来源：国家统计局，Wind，国联证券研究所来源：Wind，国家统计局，国联证券研究所图表3：医药上市公司2015年以来营业收入变化图表4：医药上市公司2011年以来归母净利润变化来源：Wind，国联证券研究所来源：Wind，国联证券研究所0%5%10%15%20%25%30%35%0500010000150002000025000300002015201620172018201920202021Q1收入（亿，左轴）增长率（%，右轴）0%10%20%30%40%50%60%70%80%90%100%050010001500200025003000350040002015201620172018201920202021Q1利润总额（亿，左轴）增长率（%，右轴）0%5%10%15%20%25%30%35%02,0004,0006,0008,00010,00012,00014,00016,00018,00020,000营业收入（左轴，亿）营收增长率（右轴，%）-20%-10%0%10%20%30%40%50%60%70%80%90%02004006008001,0001,2001,4001,6001,800归母净利(左轴，亿）归母净利增长率（右轴，%）4请务必阅读报告末页的重要声明行业点评细分板块来看，以归母净利润为主要参考指标，2020年医疗服务、医疗器械、生物制品、化学原料药的增速均在20%以上，医药商业、中药表现次之，增速在20%以下，化学制剂板块归母净利润少于去年同期。在2021年1季度，多个板块出现复苏，除中药外其他板块归母净利增速均高于20%。图表5：各子板块营收和归母净利情况来源：Wind，国联证券研究所2.1原料药原料药板块，2020年实现营收1007亿，同比增长4.87%，实现归母净利142亿，同比增长22.57%，ROE较2019年提升了0.06个百分点。2021年1季度营收增长25.61%，利润增长23.37%。一季度增长主要由于部分大宗原料药品种价格高于去年同期所致（VE、VA）。图表6：原料药企业业绩情况图表7：原料药企业ROE来源：Wind，国联证券研究所来源：Wind，国联证券研究所201920202021Q1201920202021Q1化学原料药9%5%26%65%23%23%化学制剂13%-7%14%0%-9%32%生物制品10%6%40%71%24%90%医疗服务12%15%75%-119%956%118%医疗器械14%57%104%16%143%244%医药商业16%9%28%-8%8%40%中药12%-3%20%-11%11%19%营收增长率归母净利增长率-20%-10%0%10%20%30%40%50%60%70%营收增长率归母净利增长率0%2%4%6%8%10%12%ROE5请务必阅读报告末页的重要声明行业点评原料药板块业绩在2020年提升，一是由于部分大宗原料药价格持续高位或涨价带来原料药企业业绩转暖，如肝素、生物素、VE。后续持续性方面，各产品需分别对待：肝素粗品的价格上升，降低了肝素业务的毛利；VE的竞争格局改善，预计持续向好。此外，部分CMO业务的企业，得益于中国的工程师红利、海外疫情原因订单转国内、以及研发外包的需求，业绩高速增长，这部分的企业业绩增长在2021年一季度延续。图表8：原料药利润高速增长企业业绩驱动因素来源：Wind，国联证券研究所2.2化学制剂化学制剂2020年实现营业收入3110亿元，同比减少7.30%，实现归母净利204亿元，同比减少8.58%。2021年一季度，化学制剂板块实现营收822亿元，同比增加13.68%，实现归母净利87亿元，同比增长32.34%。化学制剂医药上市公司20年ROE为5.86%，同比减少0.95个百分点。从化药企业的业绩看，2020年疫情造成的门诊量下降、用药下降的情况已逐步好转。图表9：化学制剂企业业绩图表10：化学制剂企业ROE来源：Wind，国联证券研究所来源：Wind，国联证券研究所证券代码证券简称20年归母净利增速20年扣非归母净利增速21年Q1归母净利增速21年Q1扣非归母净利增速20年扣非归母净利增加绝对额（亿）业绩驱动因素603079.SH圣达生物320%435%-63%-68%1.71生物素涨价100%，食品添加剂销量大涨600216.SH浙江医药109%167%80%158%3.67维生素E2020年以来涨价，VA销量增长002626.SZ金达威113%124%38%33%4.87辅酶Q涨价300363.SZ博腾股份75%78%83%56%1.26CMO、CRO业务增长603229.SH奥翔药业54%77%109%128%0.37肝病类原料药销量增加100%002001.SZ新和成64%76%26%24%14.76VA、VE价格景气688356.SH键凯科技39%52%230%243%0.28缓释剂型需求高603456.SH九洲药业60%42%191%211%0.95CMO业务增长603520.SH司太立40%41%41%34%0.68造影剂需求增加，毛利率改善300636.SZ同和药业45%38%28%28%0.19基数较低002399.SZ海普瑞-3%33%-44%-59%1.462020年肝素价格景气，2021年订单延后002821.SZ凯莱英30%32%43%39%1.55商业化阶段的CMO业务收入增加603707.SH健友股份33%31%34%30%1.80肝素原料药价格景气，制剂出口增加000739.SZ普洛药业48%30%40%32%1.61CMO业务增长-40%-20%0%20%40%60%营收增长率归母净利增长率0%2%4%6%8%10%12%ROE6请务必阅读报告末页的重要声明行业点评从扣非归母净利的增长角度，化学制剂板块2020年高速增长的企业为市值中等或偏小的企业。市值更大的企业，面临创新药价格谈判的机遇和集采降价的利空，两者对冲，整体表现仍旧较好。增速高的企业，包括核药（东诚）、麻醉的龙头（人福）企业、眼科用药企业（兴齐眼药）、在生产难仿药有优势的企业(博瑞)、已经在销售和创新方面都有优势的企业（贝达），以及出口恢复、集采受益的企业（华海）。2021年一季度，上述的细分领域龙头的优势得以延续。图表11：化学制剂扣非净利增长率30%以上企业来源：Wind，国联证券研究所2.3中药中药2020年实现营业收入3009亿元，同比减少2.63%，实现归母净利274亿，同比增长10.81%。2021年1季度，中药板块实现营收860亿，同比增长19.99%，实现归母净利91亿，同比增长19.33%。中药板块和化学制剂板块表现类似，疫情的影响消退。图表5：中药板块营收和归母净利增速情况图表13：中药板块ROE证券代码证券简称20年归母净利增速20年扣非归母净利增速21年Q1归母净利增速21年Q1扣非归母净利增速20年扣非归母净利增加绝对额驱动因素300573.SZ兴齐眼药145%157%418%402%0.52低浓度阿托品需求好600851.SH海欣股份15%112%81%65%0.48投资的金融企业、证券收益增加002675.SZ东诚药业170%104%-9%-10%2.00肝素涨价、核素业务增长300110.SZ华仁药业125%102%323%1015%0.45疫情使得销售费用大幅减少600521.SH华海药业63%81%16%-24%3.66原料药出口恢复，制剂集采受益300558.SZ贝达药业163%60%13%7%1.26埃克替尼快速增长688166.SH博瑞医药53%54%43%46%0.55高仿难仿品种上市带动原料药需求688658.SH悦康药业55%46%94%124%1.23心脑血管类银杏叶提取物注射液、活心丸及二甲双胍缓释片销量持续上升300705.SZ九典制药49%45%553%602%0.21低基数300158.SZ振东制药84%42%60%65%0.54朗迪钙、复方苦参、比卡鲁胺、胶体果胶铋等产品增长688189.SH南新制药45%42%-6%-35%0.37低基数600079.SH人福医药36%42%120%98%2.24麻醉药品高增长000915.SZ华特达因42%39%120%126%0.75疫情期间销售费用下降000153.SZ丰原药业28%36%28%80%0.15低基数300630.SZ普利制药35%34%51%44%0.97注射剂出口增加7请务必阅读报告末页的重要声明行业点评来源：国联证券研究所来源：国联证券研究所中药板块扣非归母净利增长30%以上、绝对金额增长较大的为红日药业、以岭药业。其中以岭药业的连花清瘟，红日药业的额温枪等医疗器械均是疫情相关药品或器械，增长较快，一季度需求延续。在2020年Q1的低基数下，2021年Q1约50%的企业扣非归母净利增速超30%。目前中药板块，尚没有像西药一样有各疾病的临床指南指导用药，学术推广上相比西药困难。在中药开具处方资格收紧的背景下，OTC类的品牌中药，或者消费属性的中药产品相对来说业绩增长较为容易。图表14：中药板块2010年净利润增速30%以上且基数较大的企业来源：国联证券研究所2.4医疗器械医疗器械板块2020年实现营业收入1976亿元，同比增长56.65%，实现归母净利498亿，同比增长143%，2021年1季度医疗器械板块实现营收600亿元，同比增长104.18%，实现归母净利润190亿元，同比增长244.42%。2020年ROE同比增长8.95个百分点，2021年一季度ROE同比增长4.16个百分点。图表15医疗器械板块营收及归母净利增速情况图表16：医疗器械板块ROE-30%-20%-10%0%10%20%30%营收增长率归母净利增长率0%2%4%6%8%10%12%14%16%ROE证券代码证券简称20年归母净利增速20年扣非归母净利增速21年Q1归母净利增速21年Q1扣非归母净利增速20年扣非归母净利增加绝对额（亿）因素002603.SZ以岭药业101%110%54%55%6.09连花清瘟受益疫情300026.SZ红日药业42%31%77%90%1.20和疫情相关的器械增长较多8请务必阅读报告末页的重要声明行业点评来源：国联证券研究所来源：国联证券研究所医疗器械板块受益疫情，整个器械板块的归母净利2020年增长约300亿。新冠检测试剂、第三方检测服务以及口罩、手套的需求拉动下，医疗器械多个子公司业绩增长从2020年延续至2021年一季度。在海外疫情反复以及国内检测常态化下，新冠检测试剂需求持续向好。图表17：医疗器械板块营收及归母净利润增速排名前列的企业情况来源：国联证券研究所2.5医疗服务医疗服务2020年实现营业收入745亿元，同比增长14.75%，实现归母净利99亿元，同比增长956%，主要是由于部分企业2019年亏损拉低了基数所致。2021年1季度医疗服务板块实现营业收入208亿，同比增加74.79%，实现归母净利29亿元（去年同期为-2亿）。0%50%100%150%200%250%300%营收增长率归母净利增长率0%5%10%15%20%25%ROE证券代码证券简称20年归母净利增速20年扣非归母净利增速21年Q1归母净利增速21年Q1扣非归母净利增速20年扣非归母净利增加绝对额驱动因素002030.SZ达安基因2557%19912%506%517%23.56新冠相关检测试剂放量688289.SH圣湘生物6528%6786%222%210%25.55新冠相关检测试剂放量300030.SZ阳普医疗525%5876%202%233%1.45新冠相关检测试剂放量300677.SZ英科医疗3829%4045%2792%2882%68.37新冠相关手套需求增加603301.SH振德医疗1525%2276%196%171%24.12新冠相关检测试剂放量688298.SH东方生物1943%2082%2601%2661%15.83新冠相关检测试剂放量002932.SZ明德生物1029%1423%17490%13459%4.25新冠相关检测试剂放量688399.SH硕世生物878%907%274%304%7.04新冠相关检测试剂放量300676.SZ华大基因656%825%275%369%18.28新冠相关检测试剂放量300869.SZ康泰医学731%771%68%68%5.27新冠相关检测试剂放量9请务必阅读报告末页的重要声明行业点评图表18：医疗服务板块营收及净利润增长情况图表19：医疗服务板块ROE来源：国联证券研究所来源：国联证券研究所医疗服务板块出现分化。CRO类的医疗服务企业整体表现较好，疫情下部分海外订单转到国内、国内的创新药研发项目审批加速、国内的工程师红利，以及一季度后国内的疫情迅速好转使得CRO类的企业表现好，该趋势在一季度继续延续，相关企业如泰格医药、康龙化成、昭衍新药、美迪西。ToC型的连锁医疗服务，美年健康、通策医疗受疫情影响，2020年业绩承压，但在2021年出现反弹。爱尔眼科在疫情下仍然维持高速增长。图表20：医疗服务板块20年净利润增速25%以上标的来源：国联证券研究所2.6医药商业医药商业板块2020年实现营业收入7794亿，同比增长9.33%；实现归母净利158亿，同比增长7.64%。2021年1季度实现营收2096亿，同比增长28.44%；实现归母净利57亿，同比增长140.40%。商业板块，连锁零售药店企业业绩表现更-200%0%200%400%600%800%1000%1200%20162017201820192020营收增长率归母净利增长率-4%-2%0%2%4%6%8%10%ROE证券代码证券简称20年归母净利增速20年扣非归母净利增速21年Q1归母净利增速21年Q1扣非归母净利增速20年扣非归母净利增加绝对额业绩驱动因素300404.SZ博济医药158%436%-226%138%0.08低基数603882.SH金域医学275%357%1023%1153%11.39第三方检测服务受益疫情688202.SH美迪西94%111%196%186%0.65CRO增长603127.SH昭衍新药77%89%388%437%1.37CRO增长300759.SZ康龙化成114%59%142%96%2.96CRO增长300015.SZ爱尔眼科25%49%510%1871%7.02连锁医疗服务增长300347.SZ泰格医药108%27%79%98%1.50CRO业务增长603259.SH药明康德60%25%395%121%4.71CRO、CMO业务增长10请务必阅读报告末页的重要声明行业点评好。图表21：医药商业板块营收及净利润增长情况图表22：医药商业板块ROE来源：国联证券研究所来源：国联证券研究所医药商业板块，连锁零售药店受疫情影响小，“内生+外延”增长模式延续。2020年，大参林新增845家门店，健之佳新增369家门店，益丰药房新增1239家门店，一心堂新增1061家门店，零售药店的增长模式使得业绩增长在一季度延续。图表23：医药商业板块20年净利润增速居前标的来源：国联证券研究所2.7生物制品生物制品板块2020年实现营业收入1288亿，同比增长5.94%；实现归母净利210亿，同比增长23.91%，2021年1季度实现营收335亿，同比增长39.60%；实现归母净利61亿，同比增长89.85%。2020年生物制品板块ROE下滑0.46个百分点，2021年1季度板块ROE提升0.76个百分点。-20%-10%0%10%20%30%40%50%营收增长率归母净利增长率0%2%4%6%8%10%12%ROE证券代码证券简称20年归母净利增速20年扣非归母净利增速21年Q1归母净利增速21年Q1扣非归母净利增速20年扣非归母净利增加绝对额业绩驱动因素603233.SH大参林51%48%22%25%3.32门店扩张（新增845家门店）605266.SH健之佳49%41%21%19%0.69新开369家门店603939.SH益丰药房41%37%26%27%2.01新增1239家门店600056.SH中国医药34%35%-19%-27%3.07出口业务增长002727.SZ一心堂31%27%27%27%1.62新增1061家直营门店11请务必阅读报告末页的重要声明行业点评图表24：生物制品板块营收及净利润增长情况图表25：生物制品板块ROE来源：国联证券研究所来源：国联证券研究所生物制品净利润表现较好的包括疫苗、生长激素、部分单抗类企业。沃森生物的13价肺炎结合疫苗上市，智飞生物的HPV疫苗放量，华兰生物的4价流感疫苗批签发量达到2千万剂；君实生物PD-1单抗放量；生长激素类的安科生物和长春高新均快速增长。消费升级、抗癌新药的需求在生物制品板块体现明显，预计增长可持续。图表26：生物制品板块归母净利润及扣非净利润增速排名前列的企业情况来源：国联证券研究所生物制品领域，疫苗、生长激素需求旺盛，新品上市、消费升级带动业绩；医药商业和医疗服务领域，连锁零售药店以及连锁医疗服务中的眼科、牙科业务依靠内生+外延扩张的模式持续，CRO/CMO类的公司受益研发项目数量增加、国内工程师红利以及海外订单转移，继续高增长；制药领域的细分龙头（麻醉、呼吸）格局好，创新药的多个企业（大分子、小分子）目前已进入收获期，建议关注以上细分板块和公司。3风险提示-40%-20%0%20%40%60%80%100%营收增长率归母净利增长率0%2%4%6%8%10%12%ROE证券代码证券简称20年归母净利增速20年扣非归母净利增速21年Q1归母净利增速21年Q1扣非归母净利增速20年扣非归母净利增加绝对额业绩驱动因素300142.SZ沃森生物607%458%277%477%5.8713价肺炎结合疫苗上市300009.SZ安科生物188%202%54%62%2.122019年有商誉减值低基数；2021年Q1生长激素高增长688180.SH君实生物-U123%120%265%265%(9.33)特瑞普利单抗放量002252.SZ上海莱士118%120%37%41%7.19GDS投资收益300841.SZ康华生物119%119%55%54%2.19狂犬疫苗放量000661.SZ长春高新72%66%61%60%11.76生长激素高增长300122.SZ智飞生物40%39%82%80%9.35HPV疫苗放量12请务必阅读报告末页的重要声明行业点评政策性风险。13请务必阅读报告末页的重要声明行业点评分析师声明本报告署名分析师在此声明：我们具有中国证券业协会授予的证券投资咨询执业资格或相当的专业胜任能力，本报告所表述的所有观点均准确地反映了我们对标的证券和发行人的个人看法。我们所得报酬的任何部分不曾与，不与，也将不会与本报告中的具体投资建议或观点有直接或间接联系。评级说明投资建议的评级标准评级说明报告中投资建议所涉及的评级分为股票评级和行业评级（另有说明的除外）。评级标准为报告发布日后6到12个月内的相对市场表现，也即：以报告发布日后的6到12个月内的公司股价（或行业指数）相对同期相关证券市场代表性指数的涨跌幅作为基准。其中：A股市场以沪深300指数为基准，新三板市场以三板成指（针对协议转让标的）或三板做市指数（针对做市转让标的）为基准；香港市场以摩根士丹利中国指数为基准；美国市场以纳斯达克综合指数或标普500指数为基准；韩国市场以柯斯达克指数或韩国综合股价指数为基准。股票评级买入相对同期相关证券市场代表指数涨幅20%以上增持相对同期相关证券市场代表指数涨幅介于5%~20%之间持有相对同期相关证券市场代表指数涨幅介于-10%~5%之间卖出相对同期相关证券市场代表指数跌幅10%以上行业评级强于大市相对同期相关证券市场代表指数涨幅10%以上中性相对同期相关证券市场代表指数涨幅介于-10%~10%之间弱于大市相对同期相关证券市场代表指数跌幅10%以上一般声明除非另有规定，本报告中的所有材料版权均属国联证券股份有限公司（已获中国证监会许可的证券投资咨询业务资格）及其附属机构（以下统称“国联证券”）。未经国联证券事先书面授权，不得以任何方式修改、发送或者复制本报告及其所包含的材料、内容。所有本报告中使用的商标、服务标识及标记均为国联证券的商标、服务标识及标记。本报告是机密的，仅供我们的客户使用，国联证券不因收件人收到本报告而视其为国联证券的客户。本报告中的信息均来源于我们认为可靠的已公开资料，但国联证券对这些信息的准确性及完整性不作任何保证。本报告中的信息、意见等均仅供客户参考，不构成所述证券买卖的出价或征价邀请或要约。该等信息、意见并未考虑到获取本报告人员的具体投资目的、财务状况以及特定需求，在任何时候均不构成对任何人的个人推荐。客户应当对本报告中的信息和意见进行独立评估，并应同时考量各自的投资目的、财务状况和特定需求，必要时就法律、商业、财务、税收等方面咨询专家的意见。对依据或者使用本报告所造成的一切后果，国联证券及/或其关联人员均不承担任何法律责任。本报告所载的意见、评估及预测仅为本报告出具日的观点和判断。该等意见、评估及预测无需通知即可随时更改。过往的表现亦不应作为日后表现的预示和担保。在不同时期，国联证券可能会发出与本报告所载意见、评估及预测不一致的研究报告。国联证券的销售人员、交易人员以及其他专业人士可能会依据不同假设和标准、采用不同的分析方法而口头或书面发表与本报告意见及建议不一致的市场评论和/或交易观点。国联证券没有将此意见及建议向报告所有接收者进行更新的义务。国联证券的资产管理部门、自营部门以及其他投资业务部门可能独立做出与本报告中的意见或建议不一致的投资决策。特别声明在法律许可的情况下，国联证券可能会持有本报告中提及公司所发行的证券并进行交易，也可能为这些公司提供或争取提供投资银行、财务顾问和金融产品等各种金融服务。因此，投资者应当考虑到国联证券及/或其相关人员可能存在影响本报告观点客观性的潜在利益冲突，投资者请勿将本报告视为投资或其他决定的唯一参考依据。无锡国联证券股份有限公司研究所江苏省无锡市太湖新城金融一街8号国联金融大厦9层电话：0510-82833337传真：0510-82833217上海国联证券股份有限公司研究所上海市浦东新区世纪大道1198号世纪汇广场1座37层电话：021-38991500传真：021-38571373","data":[{"id":"1","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2020年规模以上医药制造业实现主营业务收入24857.3亿元","content_offset":["133","164"],"indicators":[{"indicator_name":"营业收入","indicator_value":["24857.3亿元","155","164"],"indicator_element":{"时间":["2020年","133","138"],"行业":["规模以上医药制造业","138","147"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长4.5%","content_offset":["165","173"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["4.5%","169","173"],"indicator_element":{"时间":["2020年","133","138"],"行业":["规模以上医药制造业","138","147"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现利润总额3506.7亿元","content_offset":["191","205"],"indicators":[{"indicator_name":"利润总额","indicator_value":["3506.7亿元","197","205"],"indicator_element":{"时间":["2020年","133","138"],"行业":["规模以上医药制造业","138","147"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长12.80%","content_offset":["206","216"],"indicators":[{"indicator_name":"利润总额同比","indicator_value":["12.80%","210","216"],"indicator_element":{"时间":["2020年","133","138"],"行业":["规模以上医药制造业","138","147"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2021年一季度医药制造业收入为6555.1亿","content_offset":["274","297"],"indicators":[{"indicator_name":"营业收入","indicator_value":["6555.1亿","290","297"],"indicator_element":{"时间":["2021年一季度","274","282"],"行业":["医药制造业","282","287"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长30.6%","content_offset":["298","307"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["30.6%","302","307"],"indicator_element":{"时间":["2021年一季度","274","282"],"行业":["医药制造业","282","287"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"行业利润为1147.6亿元","content_offset":["308","321"],"indicators":[{"indicator_name":"营业利润","indicator_value":["1147.6亿元","313","321"],"indicator_element":{"时间":["2021年一季度","274","282"],"行业":["医药制造业","282","287"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"增速为86.88%","content_offset":["322","331"],"indicators":[{"indicator_name":"营业利润同比","indicator_value":["86.88%","325","331"],"indicator_element":{"时间":["2021年一季度","274","282"],"行业":["医药制造业","282","287"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2020年医药上市公司实现营收18928亿","content_offset":["353","374"],"indicators":[{"indicator_name":"营业收入","indicator_value":["18928亿","368","374"],"indicator_element":{"时间":["2020年","353","358"],"公司":["医药上市公司","358","364"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"增长7.18%","content_offset":["375","382"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["7.18%","377","382"],"indicator_element":{"时间":["2020年","353","358"],"公司":["医药上市公司","358","364"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利1586亿元","content_offset":["383","395"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["1586亿元","389","395"],"indicator_element":{"时间":["2020年","353","358"],"公司":["医药上市公司","358","364"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比提升44.61%","content_offset":["396","406"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["44.61%","400","406"],"indicator_element":{"时间":["2020年","353","358"],"公司":["医药上市公司","358","364"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2021年1季度实现营收5196亿","content_offset":["407","424"],"indicators":[{"indicator_name":"营业收入","indicator_value":["5196亿","419","424"],"indicator_element":{"时间":["2021年1季度","407","415"],"公司":["医药上市公司","358","364"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长31.76%","content_offset":["425","435"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["31.76%","429","435"],"indicator_element":{"时间":["2021年1季度","407","415"],"公司":["医药上市公司","358","364"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利润554亿","content_offset":["436","447"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["554亿","443","447"],"indicator_element":{"时间":["2021年1季度","407","415"],"公司":["医药上市公司","358","364"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增加84.76%","content_offset":["448","458"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["84.76%","452","458"],"indicator_element":{"时间":["2021年1季度","407","415"],"公司":["医药上市公司","358","364"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"原料药板块，2020年实现营收1007亿","content_offset":["3618","3638"],"indicators":[{"indicator_name":"营业收入","indicator_value":["1007亿","3633","3638"],"indicator_element":{"时间":["2020年","3624","3629"],"行业":["原料药","3618","3621"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长4.87%","content_offset":["3639","3648"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["4.87%","3643","3648"],"indicator_element":{"时间":["2020年","3624","3629"],"行业":["原料药","3615","3618"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利142亿","content_offset":["3649","3659"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["142亿","3655","3659"],"indicator_element":{"时间":["2020年","3624","3629"],"行业":["原料药","3615","3618"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长22.57%","content_offset":["3660","3670"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["22.57%","3664","3670"],"indicator_element":{"时间":["2020年","3624","3629"],"行业":["原料药","3615","3618"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"ROE较2019年提升了0.06个百分点","content_offset":["3671","3691"],"indicators":[{"indicator_name":"ROE同比","indicator_value":["0.06个百分点","3683","3691"],"indicator_element":{"时间":["2019年","3675","3680"],"行业":["原料药","3615","3618"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2021年1季度营收增长25.61%","content_offset":["3692","3710"],"indicators":[{"indicator_name":"营业收入增长率","indicator_value":["25.61%","3704","3710"],"indicator_element":{"时间":["2021年1季度","3692","3700"],"行业":["原料药","3615","3618"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"化学制剂2020年实现营业收入3110亿元","content_offset":["4323","4344"],"indicators":[{"indicator_name":"营业收入","indicator_value":["3110亿元","4338","4344"],"indicator_element":{"时间":["2020年","4327","4332"],"行业":["化学制剂","4323","4327"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比减少7.30%","content_offset":["4345","4354"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["减少7.30%","4347","4354"],"indicator_element":{"时间":["2020年","4327","4332"],"行业":["化学制剂","4319","4323"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利204亿元","content_offset":["4355","4366"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["204亿元","4361","4366"],"indicator_element":{"时间":["2020年","4327","4332"],"行业":["化学制剂","4319","4323"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比减少8.58%","content_offset":["4367","4376"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["减少8.58%","4369","4376"],"indicator_element":{"时间":["2020年","4327","4332"],"行业":["化学制剂","4319","4323"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2021年一季度，化学制剂板块实现营收822亿元","content_offset":["4377","4401"],"indicators":[{"indicator_name":"营业收入","indicator_value":["822亿元","4396","4401"],"indicator_element":{"时间":["2021年一季度","4377","4385"],"行业":["化学制剂","4386","4390"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增加13.68%","content_offset":["4402","4412"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["13.68%","4406","4412"],"indicator_element":{"时间":["2021年一季度","4377","4385"],"行业":["化学制剂","4319","4323"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利87亿元","content_offset":["4413","4423"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["87亿元","4419","4423"],"indicator_element":{"时间":["2021年一季度","4377","4385"],"行业":["化学制剂","4319","4323"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长32.34%","content_offset":["4424","4434"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["32.34%","4428","4434"],"indicator_element":{"时间":["2021年一季度","4377","4385"],"行业":["化学制剂","4386","4390"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"化学制剂医药上市公司20年ROE为5.86%","content_offset":["4435","4457"],"indicators":[{"indicator_name":"ROE","indicator_value":["5.86%","4452","4457"],"indicator_element":{"时间":["20年","4445","4448"],"公司":["化学制剂医药上市公司","4435","4445"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比减少0.95个百分点","content_offset":["4458","4470"],"indicators":[{"indicator_name":"ROE同比","indicator_value":["减少0.95个百分点","4460","4470"],"indicator_element":{"时间":["20年","4445","4448"],"公司":["化学制剂医药上市公司","4435","4445"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"中药2020年实现营业收入3009亿元","content_offset":["5551","5570"],"indicators":[{"indicator_name":"营业收入","indicator_value":["3009亿元","5564","5570"],"indicator_element":{"时间":["2020年","5553","5558"],"行业":["中药","5551","5553"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比减少2.63%","content_offset":["5571","5580"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["减少2.63%","5573","5580"],"indicator_element":{"时间":["2020年","5553","5558"],"行业":["中药","5549","5551"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利274亿","content_offset":["5581","5591"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["274亿","5587","5591"],"indicator_element":{"时间":["2020年","5553","5558"],"行业":["中药","5549","5551"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长10.81%","content_offset":["5592","5602"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["10.81%","5596","5602"],"indicator_element":{"时间":["2020年","5553","5558"],"行业":["中药","5549","5551"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2021年1季度，中药板块实现营收860亿","content_offset":["5603","5624"],"indicators":[{"indicator_name":"营业收入","indicator_value":["860亿","5620","5624"],"indicator_element":{"时间":["2021年1季度","5603","5611"],"行业":["中药","5612","5614"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长19.99%","content_offset":["5625","5635"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["19.99%","5629","5635"],"indicator_element":{"时间":["2021年1季度","5603","5611"],"行业":["中药","5549","5551"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利91亿","content_offset":["5636","5645"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["91亿","5642","5645"],"indicator_element":{"时间":["2021年1季度","5603","5611"],"行业":["中药","5549","5551"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长19.33%","content_offset":["5646","5656"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["19.33%","5650","5656"],"indicator_element":{"时间":["2021年1季度","5603","5611"],"行业":["中药","5549","5551"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"医疗器械板块2020年实现营业收入1976亿元","content_offset":["6718","6741"],"indicators":[{"indicator_name":"营业收入","indicator_value":["1976亿元","6735","6741"],"indicator_element":{"时间":["2020年","6724","6729"],"行业":["医疗器械","6718","6722"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长56.65%","content_offset":["6742","6752"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["56.65%","6746","6752"],"indicator_element":{"时间":["2020年","6724","6729"],"行业":["医疗器械","6714","6718"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利498亿","content_offset":["6753","6763"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["498亿","6759","6763"],"indicator_element":{"时间":["2020年","6724","6729"],"行业":["医疗器械","6714","6718"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长143%","content_offset":["6764","6772"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["143%","6768","6772"],"indicator_element":{"时间":["2020年","6724","6729"],"行业":["医疗器械","6714","6718"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2021年1季度医疗器械板块实现营收600亿元","content_offset":["6773","6796"],"indicators":[{"indicator_name":"营业收入","indicator_value":["600亿元","6791","6796"],"indicator_element":{"时间":["2021年1季度","6773","6781"],"行业":["医疗器械","6781","6785"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长104.18%","content_offset":["6797","6808"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["104.18%","6801","6808"],"indicator_element":{"时间":["2021年1季度","6773","6781"],"行业":["医疗器械","6714","6718"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利润190亿元","content_offset":["6809","6821"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["190亿元","6816","6821"],"indicator_element":{"时间":["2021年1季度","6773","6781"],"行业":["医疗器械","6714","6718"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长244.42%","content_offset":["6822","6833"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["244.42%","6826","6833"],"indicator_element":{"时间":["2021年1季度","6773","6781"],"行业":["医疗器械","6781","6785"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2020年ROE同比增长8.95个百分点","content_offset":["6834","6854"],"indicators":[{"indicator_name":"ROE同比","indicator_value":["8.95个百分点","6846","6854"],"indicator_element":{"时间":["2020年","6834","6839"],"行业":["医疗器械","6781","6785"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2021年一季度ROE同比增长4.16个百分点","content_offset":["6855","6878"],"indicators":[{"indicator_name":"ROE同比","indicator_value":["4.16个百分点","6870","6878"],"indicator_element":{"时间":["2021年一季度","6855","6863"],"行业":["医疗器械","6781","6785"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"医疗服务2020年实现营业收入745亿元","content_offset":["7336","7356"],"indicators":[{"indicator_name":"营业收入","indicator_value":["745亿元","7351","7356"],"indicator_element":{"时间":["2020年","7340","7345"],"行业":["医疗服务","7336","7340"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长14.75%","content_offset":["7357","7367"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["14.75%","7361","7367"],"indicator_element":{"时间":["2020年","7340","7345"],"行业":["医疗服务","7332","7336"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利99亿元","content_offset":["7368","7378"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["99亿元","7374","7378"],"indicator_element":{"时间":["2020年","7340","7345"],"行业":["医疗服务","7332","7336"]},"indicator_supplement":{"属性":""}}]},{"id":"54","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长956%","content_offset":["7379","7387"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["956%","7383","7387"],"indicator_element":{"时间":["2020年","7340","7345"],"行业":["医疗服务","7332","7336"]},"indicator_supplement":{"属性":""}}]},{"id":"55","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2021年1季度医疗服务板块实现营业收入208亿","content_offset":["7412","7436"],"indicators":[{"indicator_name":"营业收入","indicator_value":["208亿","7432","7436"],"indicator_element":{"时间":["2021年1季度","7412","7420"],"行业":["医疗服务","7420","7424"]},"indicator_supplement":{"属性":""}}]},{"id":"56","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增加74.79%","content_offset":["7437","7447"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["74.79%","7441","7447"],"indicator_element":{"时间":["2021年1季度","7412","7420"],"行业":["医疗服务","7420","7424"]},"indicator_supplement":{"属性":""}}]},{"id":"57","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利29亿元（去年同期为-2亿）","content_offset":["7448","7468"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["29亿元","7454","7458"],"indicator_element":{"时间":["2021年1季度","7412","7420"],"行业":["医疗服务","7420","7424"]},"indicator_supplement":{"属性":""}}]},{"id":"58","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利29亿元（去年同期为-2亿）","content_offset":["7448","7468"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["-2亿","7464","7467"],"indicator_element":{"时间":["2021年1季度","7412","7420"],"行业":["医疗服务","7420","7424"]},"indicator_supplement":{"属性":""}}]},{"id":"59","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"医药商业板块2020年实现营业收入7794亿","content_offset":["8365","8387"],"indicators":[{"indicator_name":"营业收入","indicator_value":["7794亿","8382","8387"],"indicator_element":{"时间":["2020年","8371","8376"],"行业":["医药商业","8365","8369"]},"indicator_supplement":{"属性":""}}]},{"id":"60","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长9.33%","content_offset":["8388","8397"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["9.33%","8392","8397"],"indicator_element":{"时间":["2020年","8371","8376"],"行业":["医药商业","8361","8365"]},"indicator_supplement":{"属性":""}}]},{"id":"61","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利158亿","content_offset":["8398","8408"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["158亿","8404","8408"],"indicator_element":{"时间":["2020年","8371","8376"],"行业":["医药商业","8361","8365"]},"indicator_supplement":{"属性":""}}]},{"id":"62","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长7.64%","content_offset":["8409","8418"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["7.64%","8413","8418"],"indicator_element":{"时间":["2020年","8371","8376"],"行业":["医药商业","8361","8365"]},"indicator_supplement":{"属性":""}}]},{"id":"63","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2021年1季度实现营收2096亿","content_offset":["8419","8436"],"indicators":[{"indicator_name":"营业收入","indicator_value":["2096亿","8431","8436"],"indicator_element":{"时间":["2021年1季度","8419","8427"],"行业":["医药商业","8361","8365"]},"indicator_supplement":{"属性":""}}]},{"id":"64","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长28.44%","content_offset":["8437","8447"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["28.44%","8441","8447"],"indicator_element":{"时间":["2021年1季度","8419","8427"],"行业":["医药商业","8361","8365"]},"indicator_supplement":{"属性":""}}]},{"id":"65","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利57亿","content_offset":["8448","8457"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["57亿","8454","8457"],"indicator_element":{"时间":["2021年1季度","8419","8427"],"行业":["医药商业","8361","8365"]},"indicator_supplement":{"属性":""}}]},{"id":"66","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长140.40%","content_offset":["8458","8469"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["140.40%","8462","8469"],"indicator_element":{"时间":["2021年1季度","8419","8427"],"行业":["医药商业","8361","8365"]},"indicator_supplement":{"属性":""}}]},{"id":"67","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"生物制品板块2020年实现营业收入1288亿","content_offset":["9188","9210"],"indicators":[{"indicator_name":"营业收入","indicator_value":["1288亿","9205","9210"],"indicator_element":{"时间":["2020年","9194","9199"],"行业":["生物制品","9188","9192"]},"indicator_supplement":{"属性":""}}]},{"id":"68","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长5.94%","content_offset":["9211","9220"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["5.94%","9215","9220"],"indicator_element":{"时间":["2020年","9194","9199"],"行业":["生物制品","9184","9188"]},"indicator_supplement":{"属性":""}}]},{"id":"69","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利210亿","content_offset":["9221","9231"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["210亿","9227","9231"],"indicator_element":{"时间":["2020年","9194","9199"],"行业":["生物制品","9184","9188"]},"indicator_supplement":{"属性":""}}]},{"id":"70","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长23.91%","content_offset":["9232","9242"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["23.91%","9236","9242"],"indicator_element":{"时间":["2020年","9194","9199"],"行业":["生物制品","9184","9188"]},"indicator_supplement":{"属性":""}}]},{"id":"71","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2021年1季度实现营收335亿","content_offset":["9243","9259"],"indicators":[{"indicator_name":"营业收入","indicator_value":["335亿","9255","9259"],"indicator_element":{"时间":["2021年1季度","9243","9251"],"行业":["生物制品","9184","9188"]},"indicator_supplement":{"属性":""}}]},{"id":"72","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长39.60%","content_offset":["9260","9270"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["39.60%","9264","9270"],"indicator_element":{"时间":["2021年1季度","9243","9251"],"行业":["生物制品","9184","9188"]},"indicator_supplement":{"属性":""}}]},{"id":"73","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"实现归母净利61亿","content_offset":["9271","9280"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["61亿","9277","9280"],"indicator_element":{"时间":["2021年1季度","9243","9251"],"行业":["生物制品","9184","9188"]},"indicator_supplement":{"属性":""}}]},{"id":"74","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"同比增长89.85%","content_offset":["9281","9291"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["89.85%","9285","9291"],"indicator_element":{"时间":["2021年1季度","9243","9251"],"行业":["生物制品","9184","9188"]},"indicator_supplement":{"属性":""}}]},{"id":"75","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2020年生物制品板块ROE下滑0.46个百分点","content_offset":["9292","9316"],"indicators":[{"indicator_name":"ROE","indicator_value":["下滑0.46个百分点","9306","9316"],"indicator_element":{"时间":["2020年","9292","9297"],"行业":["生物制品","9297","9301"]},"indicator_supplement":{"属性":""}}]},{"id":"76","source_document":"医药生物行业：整体受益疫情，建议关注高成长可持续板块.pdf","content":"2021年1季度板块ROE提升0.76个百分点","content_offset":["9317","9340"],"indicators":[{"indicator_name":"ROE","indicator_value":["0.76个百分点","9332","9340"],"indicator_element":{"时间":["2021年1季度","9317","9325"],"行业":["生物制品","9297","9301"]},"indicator_supplement":{"属性":""}}]}]}